Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Mehmet Altan,Yan Wang,Juhee Song,James Welsh,Chad Tang,Nandita Guha-Thakurta,George R Blumenschein,Brett W Carter,Jeffrey S Wefel,Amol J Ghia,Debra N Yeboa,Mary Frances McAleer,Caroline Chung,Kristina D Woodhouse,Susan L McGovern,Chenyang Wang,Betty Y S Kim,Jeffrey S Weinberg,Tina M Briere,Yasir Y Elamin,Xiuning Le,Tina Cascone,Marcelo V Negrao,Ferdinandos Skoulidis,Renata Ferrarotto,John V Heymach,Jing Li,Xiuning Lee
DOI: https://doi.org/10.1136/jitc-2023-006871
IF: 12.469
2023-07-01
Journal for ImmunoTherapy of Cancer
Abstract:Background Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery. There are no prospective data on the safety of stereotactic radiosurgery (SRS) concurrent with immune checkpoint inhibitor therapy for BM. This is the safety cohort of the phase I/II investigator-initiated trial of SRS with nivolumab and ipilimumab for patients with BM from NSCLC. Patients and methods This single-institution study included patients with NSCLC with active BM amenable to SRS. Brain SRS and systemic therapy with nivolumab and ipilimumab were delivered concurrently (within 7 days). The endpoints were safety and 4-month intracranial progression-free survival (PFS). Results Thirteen patients were enrolled in the safety cohort, 10 of whom were evaluable for dose-limiting toxicities (DLTs). Median follow-up was 23 months (range 9.7–24.3 months). The median interval between systemic therapy and radiation therapy was 3 days. Only one patient had a DLT; hence, predefined stopping criteria were not met. In addition to the patient with DLT, three patients had treatment-related grade ≥3 adverse events, including elevated liver function tests, fatigue, nausea, adrenal insufficiency, and myocarditis. One patient had a confirmed influenza infection 7 months after initiation of protocol treatment (outside the DLT assessment window), leading to pneumonia and subsequent death from hemophagocytic lymphohistiocytosis. The estimated 4-month intracranial PFS rate was 70.7%. Conclusion Concurrent brain SRS with nivolumab/ipilimumab was safe for patients with active NSCLC BM. Preliminary analyses of treatment efficacy were encouraging for intracranial treatment response.
oncology,immunology